Improved survival in multiple myeloma and the impact of novel therapies.

Blood 2008 Mar 1;111(5):2516-20. Epub 2007 Nov 1.

Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends over time. Among 387 patients relapsing after stem-cell transplantation, a clear improvement in overall survival from the time of relapse was seen, with those relapsing after 2000 having a median overall survival of 23.9 versus 11.8 months (P < .001) for those who relapsed prior to this date. This improvement was independent of other prognostic factors. Patients treated with one or more of the newer drugs (thalidomide, lenalidomide, bortezomib) had longer survival from relapse (30.9 vs 14.8 months; P < .001). In a larger group of 2981 patients with newly diagnosed myeloma, those diagnosed in the last decade had a 50% improvement in overall survival (44.8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis.

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-10-11
Publisher Site
http://dx.doi.org/10.1182/blood-2007-10-116129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2254544PMC
March 2008
5 Reads

Publication Analysis

Top Keywords

months 001
12
outcome patients
8
novel therapies
8
patients myeloma
8
improvement survival
8
time relapse
8
patients
6
myeloma
5
survival
5
2000 median
4
50% improvement
4
median survival
4
relapsing 2000
4
diagnosed decade
4
decade 50%
4
relapse relapsing
4
239 versus
4
survival 239
4
transplantation clear
4
time 387
4

References

(Supplied by CrossRef)
Global cancer statistics, 2002.
Parkin et al.
CA Cancer J Clin 2005
Cancer statistics, 2007.
Jemal et al.
CA Cancer J Clin 2007
The survival time of patients with plasmocytic myeloma.
Osgood et al.
Cancer Chemother Rep 1960
Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma, IV: L-Phenylalanine mustard (NSC-8806).
Bergsagel et al.
Cancer Chemother Rep 1962

Similar Publications